/Companies

Convexia

YC S25

San Francisco, US · Founded 2025 · 4 employees · 14 known investors

Find your way into Convexia

Sign up to see every warm intro you have to Convexia

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Convexia team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Convexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity. The platform combines AI agents with expert human review to accelerate drug asset evaluation for biotech companies, pharma firms, and venture investors.

Founders & leadership· Y Combinator alumni (S25)

Convexia was founded in 2025 by Ayaan Parikh and Rahul Vijayan.

APAyaan Parikh
Ayaan ParikhCo-Founder & CEOAyaan Parikh holds degrees in computer science and biology from Stanford. He has founded three healthtech startups spanning telemedicine, addiction recovery, and hydroponic systems, and has published research on molecular dynamics. His background also includes experience in biotech venture capital and consulting.
RVRahul Vijayan
Rahul VijayanCo-Founder & CTORahul Vijayan studied computer science and economics at Stanford. He previously founded three healthtech companies in telemedicine, recovery optimization, and agricultural systems.
AP
Ayaan Parikh Rahul VijayanFounder

Investors · 14

Aliaksandr Hudzilinreported

How we know: Y Combinator's founder network · Not right? Tell us

Blast.Clubreported$5.5M

How we know: Y Combinator's founder network · Not right? Tell us

ETA Capital PartnersreportedBoston

How we know: Y Combinator's founder network · Not right? Tell us

Exit Venturesreported

How we know: Y Combinator's founder network · Not right? Tell us

OurCrowdreportedJerusalem

How we know: Y Combinator's founder network · Not right? Tell us

Panacea VenturereportedSingapore

How we know: Y Combinator's founder network · Not right? Tell us

Phosphor Capitalreported

How we know: Y Combinator's founder network · Not right? Tell us

Venture Investment AssociatesreportedPeapack

How we know: Y Combinator's founder network · Not right? Tell us

The YC application· Summer 2025 batch

Alumni Q&A

How did your company get started? (i.e., How did the founders meet? How did you come up with the idea? How did you decide to be a founder?)
The two founders, Ayaan and Rahul, met at an entrepreneurship conference in 8th grade and have built companies together since. They launched two startups during high school and a third at Stanford, which was later acquired. Convexia is their fourth venture.

Summarized from the founders' answers on their Y Combinator profile.

Related companies · 6

EvecxiaEvecxia Therapeutics develops 5-HTP-based drugs using proprietary drug delivery technologies designed to increase brain serotonin production as adjunctive treatments for depression and other mental disorders. Its therapies target patients with disabling mental illness not adequately treated by existing antidepressants such as SSRIs and SNRIs.
Synthio LabsSynthio Labs develops AI-powered synthesis and clinical interpretation systems for pharmaceutical interactions, offering text, voice, and video interfaces designed for healthcare professionals and patients that integrate FDA labels, drug mechanisms, and clinical literature.
TheoraTheora partners with Indian healthcare organizations to aggregate, structure, and de-identify clinical and genomic data for pharmaceutical and AI research, addressing the underrepresentation of Indian populations in drug discovery and genetic studies.
Cybrexa, Inc.Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
Multiply LabsMultiply Labs builds robotic systems that automate biologics manufacturing for pharmaceutical companies. The platform orchestrates existing laboratory instruments in a closed, sterile environment to increase throughput by up to 100x while reducing costs and contamination risk.
NanograbNanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.

Companies working in the same space as Convexia.

Legal entities · 1

corporate structure
Convexia, Inc.

In the news

Frequently asked questions

What does Convexia do?
Convexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity. The platform combines AI agents with expert human review to accelerate drug asset evaluation for biotech companies, pharma firms, and venture investors.
Who founded Convexia?
Convexia was founded by Ayaan Parikh, Rahul Vijayan in 2025.
Who are Convexia's investors?
Convexia's investors include Gaingels, Gravity, Maiora Rebel Ventures, Rebel Fund, Y Combinator, Aliaksandr Hudzilin, Basis Set Ventures, Blast.Club and 6 more.
Where is Convexia headquartered?
Convexia is headquartered in San Francisco, US.